These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1621012)

  • 21. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
    Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
    Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spinocerebellar degeneration and neuropeptides.
    Matsuoka Y; Sakurai N
    Jpn J Med; 1989; 28(6):791-3. PubMed ID: 2517445
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease.
    Mellow AM; Sunderland T; Cohen RM; Lawlor BA; Hill JL; Newhouse PA; Cohen MR; Murphy DL
    Psychopharmacology (Berl); 1989; 98(3):403-7. PubMed ID: 2501817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Alteration of CBF and CMRO2 and TRH effects on CBF in spinocerebellar degeneration. The positron emission tomography study].
    Harada K; Fukuyama H; Miyoshi T; Namura Y; Kameyama M
    Rinsho Shinkeigaku; 1988 May; 28(5):563-8. PubMed ID: 3145826
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of pathologic emotionality with thyrotropin-releasing hormone.
    Komurasaki Y; Yokoyama T; Ogura J; Maeda K
    Jpn J Psychiatry Neurol; 1989 Dec; 43(4):665-8. PubMed ID: 2517762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis.
    Caroscio JT; Cohen JA; Zawodniak J; Takai V; Shapiro A; Blaustein S; Mulvihill MN; Loucas SP; Gudesblatt M; Rube D
    Neurology; 1986 Feb; 36(2):141-5. PubMed ID: 3080693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy.
    Kato Z; Okuda M; Okumura Y; Arai T; Teramoto T; Nishimura M; Kaneko H; Kondo N
    J Child Neurol; 2009 Aug; 24(8):1010-2. PubMed ID: 19666885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRH and spinocerebellar degeneration.
    LeWitt PA; Ehrenkranz JR
    Lancet; 1982 Oct; 2(8305):981. PubMed ID: 6127475
    [No Abstract]   [Full Text] [Related]  

  • 29. Thyrotropin-releasing hormone (TRH) inchronic schizophrenia. A controlled study.
    Lindström LH; Gunne LM; Ost LG; Persson E
    Acta Psychiatr Scand; 1977 Jan; 55(1):74-80. PubMed ID: 402794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials.
    Mitsumoto H; Salgado ED; Negroski D; Hanson MR; Salanga VD; Wilber JF; Wilbourn AJ; Breuer AC; Leatherman J
    Neurology; 1986 Feb; 36(2):152-9. PubMed ID: 3080695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Spinocerebellar degeneration].
    Sugai Y
    Ryoikibetsu Shokogun Shirizu; 2003; (40):272-4. PubMed ID: 14626118
    [No Abstract]   [Full Text] [Related]  

  • 32. Low-dose thyrotropin-releasing hormone effects in cognitively impaired alcoholics.
    Khan A; Mirolo MH; Claypoole K; Hughes D
    Alcohol Clin Exp Res; 1993 Aug; 17(4):791-6. PubMed ID: 8214416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma thyrotropin-releasing hormone, prolactin, thyrotropin, and thyroxine concentrations following the intravenous or oral administration of thyrotropin-releasing hormone.
    Andreassen B; Huth J; Tyson JE
    Am J Obstet Gynecol; 1979 Nov; 135(6):737-42. PubMed ID: 115316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder.
    Isogawa K; Nagayama H; Tsutsumi T; Kiyota A; Akiyoshi J; Hieda K
    J Psychiatr Res; 2005 Sep; 39(5):467-73. PubMed ID: 15992555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of progressive myoclonus epilepsy with TRH.
    Tanaka C; Maegaki Y; Koeda T; Ohta S; Takeshita K
    Pediatr Neurol; 1998 May; 18(5):442-4. PubMed ID: 9650689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system.
    Ijiro T; Nakamura K; Ogata M; Inada H; Kiguchi S; Maruyama K; Nabekura J; Kobayashi M; Ishibashi H
    Eur J Pharmacol; 2015 Aug; 761():413-22. PubMed ID: 26142830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Amine metabolites in cerebrospinal fluids and thyrotropin releasing hormone in spinocerebellar degeneration].
    Arai M
    Rinsho Shinkeigaku; 1988 Jun; 28(6):595-604. PubMed ID: 2466598
    [No Abstract]   [Full Text] [Related]  

  • 38. Pitch discrimination in cerebellar patients: evidence for a sensory deficit.
    Parsons LM; Petacchi A; Schmahmann JD; Bower JM
    Brain Res; 2009 Dec; 1303():84-96. PubMed ID: 19766609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone].
    Serratrice G; Desnuelle C; Crevat A; Guelton C; Meyer-Dutour A
    Rev Neurol (Paris); 1986; 142(2):133-9. PubMed ID: 3088700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyrotropin-releasing hormone in acute pancreatitis. A preliminary report.
    Kiviniemi H; Laitinen S; Ståhlberg M; Larmi M; Kairaluoma M
    Acta Chir Scand; 1986 Jan; 152():43-7. PubMed ID: 2420106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.